CLINICAL TRIALS PROFILE FOR OPICAPONE
✉ Email this page to a colleague
All Clinical Trials for Opicapone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01227655 ↗ | Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. | Completed | Bial - Portela C S.A. | Phase 3 | 2011-03-01 | Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year. BIA 9-1067 is currently being developed by BIAL (Portela & CÂȘ,S.A.) to be used in addition to L-DOPA (Levodopa) /carbidopa or L-DOPA (Levodopa) / preparations in PD patients. Promising results have been obtained for BIA 9-1067 in previous studies. |
NCT01515891 ↗ | Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites | Completed | Bial - Portela C S.A. | Phase 1 | 2009-05-01 | To determine the absorption, metabolism and excretion of BIA 9-1067. |
NCT01851850 ↗ | Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial | Completed | Rabin Medical Center | Phase 3 | 2013-05-01 | The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years. |
NCT02101190 ↗ | Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment | Completed | Bial - Portela C S.A. | Phase 1 | 2010-03-01 | The purpose of this study is to assess the pharmacokinetics (PK) of BIA 9-1067 in patients with moderate chronic hepatic impairment and in matched healthy subjects. |
NCT02170376 ↗ | The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics | Completed | Bial - Portela C S.A. | Phase 1 | 2011-09-01 | The purpose of this study is to determine the effect of repeated dosing of once-daily 25, 50 and 75 mg opicapone (OPC, development code BIA 9-1067) on the levodopa pharmacokinetics (PK), in comparison to placebo and 200 mg entacapone (ENT). |
NCT02305017 ↗ | Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers | Completed | Bial - Portela C S.A. | Phase 1 | 2014-03-01 | Single-centre, open-label, randomised, two-way cross-over study consisting of 2 periods separated by a washout period of 14 days or more. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Opicapone
Condition Name
Clinical Trial Locations for Opicapone
Trials by Country
Clinical Trial Progress for Opicapone
Clinical Trial Phase
Clinical Trial Sponsors for Opicapone
Sponsor Name